摘要
目的：探讨阿立哌唑与利培酮治疗Ⅱ型精神分裂症患者的临床疗效和安全性。方法将120例Ⅱ型精神分裂症患者随机分为两组，观察组口服阿立哌唑治疗，对照组口服利培酮治疗，观察12周。于治疗前后采用阳性与阴性症状量表评定临床疗效，采用韦氏成人智力量表、韦氏记忆量表及韦斯康星卡片分类测验评定认知功能，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降，言语量表、操作量表、全量表和记忆量表评分均较治疗前显著升高（ P＜0．01）；治疗12周末，观察组有效率为85．0％，对照组为88．3％，两组比较差异无显著性（ P＞0．05）。两组不良反应均轻微，但观察组锥体外系反应、泌乳/闭经、体质量增加、血糖升高发生率显著低于对照组（ P＜0．05或0．01）。结论阿立哌唑治疗Ⅱ型精神分裂症疗效显著，总体疗效与利培酮相当，但阿立哌唑治疗安全性更高，依从性更好。
Objective To explore the efficacy and safety of aripiprazole vs .risperidone in type II schizo-phrenia .Methods A total of 120 patients with type Ⅱ schizophrenia were randomly divided into two groups ,observation group took orally aripiprazole and control group did risperidone for 12 weeks .Before and after treatment efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） ,cog-nitive fundions with the WAIS-R ,WMS and WCST and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results After treatment the total and each factor scores of both groups lowered more significantly compared with pre-treatment ,verbal ,performance ,full and memory scale score height-ened （P〈0 .01）;at the end of 12th week effective rate were respectively 85 .0% in observation and 88 .3%in control group ,which showed no significant difference （P〉 0 .05） .Adverse reactions of both groups were mild ,but the incidence of extrapyramidal reaction ,lactation/amenorrhea ,weight gain ,blood glu-cose elevation were significantly lower in observation than control group （P〈0 .05 or 0 .01） .Conclusion Aripiprazole has an evident effect equivalent to risperidone in the treatment of type II schizophrenia ,but the former has higher safety and better compliance .
出处
《临床心身疾病杂志》
CAS
2013年第6期511-513,共3页
Journal of Clinical Psychosomatic Diseases
基金
新乡医学院重点开放课题（编号：ZD200993）
